National Institute of Allergy and Infectious Diseases (NIAID) clinical trial pipeline

27 trials changed in the last 30 days: 0 stopped, 13 with notable changes, 14 with minor changes only.

1. Notable

   Mechanistic Biology of Primary Immunodeficiency Disorders

   Primary completion pushed from Dec 31, 2029 to Dec 31, 2030

   And 1 more change in the last 30 days

   National Institute of Allergy and Infectious Diseases (NIAID)·Not specified· NCT03394053· Registry history of NCT03394053 on ClinicalTrials.gov (opens the registry)

   Updated Oct 8, 2026

2. Notable

   Immune Response to Ixodes Scapularis Tick Bites

   Primary and study completion pushed from Jun 30, 2028 to Jun 30, 2029

   National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2· NCT05036707· Registry history of NCT05036707 on ClinicalTrials.gov (opens the registry)

   Updated Sep 18, 2026

3. Notable

   ZENITH · Tezepelumab in Peanut Oral Immunotherapy

   Primary and study completion pushed from Sep 16, 2028 to May 2029

   National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2· NCT07015996· Registry history of NCT07015996 on ClinicalTrials.gov (opens the registry)

   Updated Sep 16, 2026

4. Notable

   VIBRANT · VIB4920 for Active Lupus Nephritis

   Primary completion pushed from Aug 2026 to Jun 2028

   Also in this update: Completion pushed from Mar 2027 to Dec 2028

   National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2· NCT05201469· Registry history of NCT05201469 on ClinicalTrials.gov (opens the registry)

   Updated Sep 16, 2026

5. Notable

   Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in…Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706

   Primary completion pushed from Jul 27, 2026 to Nov 30, 2027

   Also in this update: Completion pushed from May 4, 2027 to Nov 30, 2027

   National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1· NCT06665646· Registry history of NCT06665646 on ClinicalTrials.gov (opens the registry)

   Updated Sep 18, 2026

6. Notable

   Novel Genetic Disorders of the Immune System

   Primary and study completion pushed from Aug 30, 2026 to Aug 30, 2027

   National Institute of Allergy and Infectious Diseases (NIAID)·Not specified· NCT02257892· Registry history of NCT02257892 on ClinicalTrials.gov (opens the registry)

   Updated Sep 14, 2026

7. Notable

   ALL IN LUNG · Tocilizumab in Lung Transplantation

   Enrollment reduced: 350 → 100 participants

   National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2· NCT06033196· Registry history of NCT06033196 on ClinicalTrials.gov (opens the registry)

   Updated Oct 8, 2026

8. Notable

   Orally Ingested Yeast Modified to Express a Tetra-specific…Orally Ingested Yeast Modified to Express a Tetra-specific Anti-toxin for Clostridioides Difficile

   Enrollment reduced: 86 → 56 participants

   Also in this update: Trial arms changed: 14 → 8

   National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1· NCT07649096· Registry history of NCT07649096 on ClinicalTrials.gov (opens the registry)

   Updated Oct 6, 2026

9. Notable

   CH505 HIV Vaccine Nanoparticles and mRNA Boosters in Healthy…CH505 HIV Vaccine Nanoparticles and mRNA Boosters in Healthy Adults

   Recruitment opened

   Also in this update: Start date pushed from Oct 1, 2026 to Oct 19, 2026

   National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1· NCT07757802· Registry history of NCT07757802 on ClinicalTrials.gov (opens the registry)

   Updated Oct 9, 2026

10. Notable

    Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy…Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy · CXCR4-WHIM

    Enrolling by invitation only

    National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2· NCT07775313· Registry history of NCT07775313 on ClinicalTrials.gov (opens the registry)

    Changed Sep 16, 2026

11. Notable

    PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1)

    Trial status changed: Suspended → Withdrawn

    National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1· NCT05652504· Registry history of NCT05652504 on ClinicalTrials.gov (opens the registry)

    Updated Sep 16, 2026

12. Notable

    Tocilizumab in Cardiac Transplantation

    Results posted: Sep 29, 2026

    National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2· NCT03644667· Registry history of NCT03644667 on ClinicalTrials.gov (opens the registry)

    Updated Sep 29, 2026

13. Notable

    Infectivity, Safety and Immunogenicity of Two Recombinant…Infectivity, Safety and Immunogenicity of Two Recombinant, Live-Attenuated, B/HPIV3 Vectored Vaccines Expressing the Fusion Glycoprotein of HMPV Delivered by Nasal Spray to HPIV3-Seropositive Children 24 to <60 Months of Age

    Results posted: Sep 18, 2026

    National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1· NCT06546423· Registry history of NCT06546423 on ClinicalTrials.gov (opens the registry)

    Updated Sep 18, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.